drugset
drugset / Trial / NCT01103037

Efficacy, Safety and Pharmacokinetics of QAV680 Versus Placebo in Patients With Asthma

NCT01103037 ↗

Phase 2 Terminated 8 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will assess the safety and efficacy of QAV680 in patients with mild to moderate asthma

Timeline

Start
2010-03
Primary completion
2010-09
Completion
2010-09

Drugs

EvaluationDrugModalityDoseRoute
Subject QAV680 Small molecule 500 mg —

Indications

asthma